Pro-inflammatory activation of monocytes in patients with immunoinflammatory rheumatic diseases

The pathogenesis of immunoinflammatory rheumatic diseases (IRDs) is based on chronic inflammation, one of the key mechanisms of which may be abnormal activation of macrophages, leading to further disruption of the immune system.

The aim – to evaluate the pro-inflammatory activation of circulating monocytes in patients with IRDs.

Material and methods. The study included 149 participants: 53 patients with rheumatoid arthritis (RA), 45 – with systemic lupus erythematosus (SLE), 34 – with systemic scleroderma (SSc) and 17 participants without IRD, aged 30 to 65 years. Basal and lipolysaccharide (LPS)-stimulated secretion of monocytes was studied in a primary culture of monocytes obtained by immunomagnetic separation from blood. Quantitative assessment of the cytokines tumor necrosis factor-α (TNF-α), interleukin 1β (IL-1β) and the monocyte chemoattractant protein-1 (MCP-1) was carried out in the culture fluid by ELISA. Pro-inflammatory activation of monocytes was calculated as the ratio of LPS-stimulated and basal secretions.

Results. It was shown that the basal secretion of all studied cytokines was significantly increased in all groups of patients with IRDs, except for the secretion of IL-1β in the SLE group, compared with the control. LPS-stimulated secretion of TNF-α was increased and MCP-1 was decreased in patients with IRDs compared to the control group; LPS-stimulated IL-1β secretion only in the SSc group was significantly different from the control group. In the RA group, monocyte activation was reduced for all cytokines compared to the control, in the SLE group – for TNF-α and MCP-1, in the SSc group – for MCP-1.

Conclusion. The decrease in pro-inflammatory activation of monocytes in patients with IRDs is due to a high level of basal secretion of cytokines, which can lead to disruption of the adequate immune response in these diseases and is an important link in the pathogenesis of chronic inflammation.

1. Kouchit Y, Morand L, Martis N. Mortality and its risk factors in critically ill patients with connective tissue diseases: A meta-analysis. Eur J Intern Med. 2022;98:83-92. doi: 10.1016/j.ejim.2022.02.006

2. Nasonov EL, Lila AM, Dubinina TV, Nikininskaya OA, Amirdjanova VN. Advances in rheumatology at the beginning of the 21st century. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2022;60(1):5-20 (In Russ.). doi: 10.47360/1995-4484-2022-5-20

3. Ahsan H. Selfie: Autoimmunity, boon or bane. J Immunoassay Immunochem. 2017;38(3):235-246. doi: 10.1080/15321819.2017.1319861

4. Yang S, Zhao M, Jia S. Macrophage: Key player in the pathogenesis of autoimmune diseases. Front Immunol. 2023;14;14:1080310. doi: 10.3389/fimmu.2023.1080310

5. Nasonov EL, Avdeeva AS. Interleukin 18 in Immune-mediated rheumatic diseases and COVID-19. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2022;60(2):195-204 (In Russ.). doi: 10.47360/1995-4484-2022-195-204

6. Ma WT, Gao F, Gu K, Chen DK. The role of monocytes and macrophages in autoimmune diseases: A comprehensive review. Front Immunol. 2019;10:1140. doi: 10.3389/fimmu.2019.01140

7. Navegantes KC, de Souza Gomes R, Pereira PAT, Czaikoski PG, Azevedo CHM, Monteiro MC. Immune modulation of some autoimmune diseases: The critical role of macrophages and neutrophils in the innate and adaptive immunity. J Transl Med. 2017;15(1):36. doi: 10.1186/s12967-017-1141-8

8. Pang J, Koh TJ. Proliferation of monocytes and macrophages in homeostasis, infection, injury and disease. J Leukoc Biol. 2023;9:qiad093. doi: 10.1093/jleuko/qiad093

9. Gerasimova EV, Popkova TV. Macrophage functional disorders in rheumatoid arthritis and atherosclerosis. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2018;56(4):486-493 (In Russ.). doi: 10.14412/1995-4484-2018-486-493

10. Prajzlerová K, Kryštůfková O, Komarc M, Mann H, Hulejová H, Petrovská N, et al. The dysregulation of monocyte subpopulations in individuals at risk of developing rheumatoid arthritis. Rheumatology (Oxford). 2021;60(4):1823-1831. doi: 10.1093/rheumatology/keaa518

11. Wang Y, Han CC, Cui D, Li Y, Ma Y, Wei W. Is macrophage polarization important in rheumatoid arthritis? Int Immunopharmacol. 2017;50:345-352. doi: 10.1016/j.intimp.2017.07.019

12. Byrne JC, Ní Gabhann J, Lazzari E, Mahony R, Smith S, Stacey K, et al. Genetics of SLE: Functional relevance for monocytes/macrophages in disease. Clin Dev Immunol. 2012;2012:582352. doi: 10.1155/2012/582352

13. Kwant LE, Vegting Y, Tsang-A-Sjoe MWP, Kwakernaak AJ, Vogt L, Voskuyl AE, et al. Macrophages in lupus nephritis: Exploring a potential new therapeutic avenue. Autoimmun Rev. 2022;21(12):103211. doi: 10.1016/j.autrev.2022.103211

14. Higashi-Kuwata N, Jinnin M, Makino T, Fukushima S, Inoue Y, Muchemwa FC, et al. Characterization of monocyte/macrophage subsets in the skin and peripheral blood derived from patients with systemic sclerosis. Arthritis Res Ther. 2010;12(4):R128. doi: 10.1186/ar3066

15. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, et al. 2010 rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569-2581. doi: 10.1002/art.27584

16. Petri M, Orbai AM, Alarcón GS, Gordon C, Merrill JT, Fortin PR, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64(8):2677-2686. doi: 10.1002/art.34473

17. van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013 classification criteria for systemic sclerosis: An American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis. 2013;72(11): 1747-1755. doi: 10.1136/annrheumdis-2013-204424

18. Crayne CB, Albeituni S, Nichols KE, Cron RQ. The immunology of macrophage activation syndrome. Front Immunol. 2019;10:119. doi: 10.3389/fimmu.2019.00119

19. Goldring SR. Pathogenesis of bone erosions in rheumatoid arthritis. Curr Opin Rheumatol. 2002;14(4):406-410. doi: 10.1097/00002281-200207000-00013

20. Lama M, Sarkar R, Ghosh B. Serum cytokine profiles in patients with rheumatoid arthritis before and after treatment with methotrexate. J Interferon Cytokine Res. 2023;43(8):344-350. doi: 10.1089/jir.2023.0078

21. Lapkina NA, Baranov AA, Abaytova NE, Levshin NYu, Avdeyeva AS, Leontyeva EA, et al. Dynamics of clinical manifestations and cytokine concentrations in rheumatoid arthritis patients on tofacitinib therapy. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2021;59(6):693-699 (In Russ.). doi: 10.47360/1995-4484-2021-693-699

22. Pehlivan Y, Onat AM, Ceylan N, Turkbeyler IH, Buyukhatipoglu H, Comez G, et al. Serum leptin, resistin and TNF-α levels in patients with systemic sclerosis: The role of adipokines in scleroderma. Int J Rheum Dis. 2012;15(4):374-379. doi: 10.1111/j.1756-185X.2012.01755.x

23. Zhao R, Zhou H, Su SB. A critical role for interleukin-1β in the progression of autoimmune diseases. Int Immunopharmacol. 2013;17(3):658-669. doi: 10.1016/j.intimp.2013.08.012

24. Voronov E, Dayan M, Zinger H, Gayvoronsky L, Lin JP, Iwakura Y, et al. IL-1 beta-deficient mice are resistant to induction of experimental SLE. Eur Cytokine Netw. 2006;17(2):109-116.

25. Italiani P, Manca ML, Angelotti F, Melillo D, Pratesi F, Puxeddu I, et al. IL-1 family cytokines and soluble receptors in systemic lupus erythematosus. Arthritis Res Ther. 2018;20(1):27. doi: 10.1186/s13075-018-1525-z

26. Mähönen K, Hau A, Bondet V, Duffy D, Eklund KK, Panelius J, et al. Activation of NLRP3 inflammasome in the skin of patients with systemic and cutaneous lupus erythematosus. Acta Derm Venereol. 2022;102:adv00708. doi: 10.2340/actadv.v102.2293

27. Moadab F, Khorramdelazad H, Abbasifard M. Role of CCL2/ CCR2 axis in the immunopathogenesis of rheumatoid arthritis: Latest evidence and therapeutic approaches. Life Sci. 2021;269:119034. doi: 10.1016/j.lfs.2021.119034

28. Kuuliala K, Kuuliala A, Hämäläinen M, Koivuniemi R, Kautiainen H, Moilanen E, et al. Impaired Akt phosphorylation in monocytes of patients with rheumatoid arthritis. Scand J Immunol. 2017;85(2):155-161. doi: 10.1111/sji.12521